Understanding the role of Annexin A2 expression in the incidence of Hepatocellular Carcinoma.
dc.creator | Fiadjoe, Hope | en_US |
dc.creator | Chaudhary, Pankaj | en_US |
dc.date.accessioned | 2024-04-16T18:48:03Z | |
dc.date.available | 2024-04-16T18:48:03Z | |
dc.date.issued | 2024-03-21 | en_US |
dc.description.abstract | Purpose: Hepatocellular carcinoma (HCC) is a rapidly growing cancer with high mortality rates worldwide, necessitating improved diagnostic and therapeutic strategies. Annexin A2 (AnxA2), a calcium-dependent phospholipid-binding protein and a member of the annexin protein family, holds promise as a diagnostic, prognostic, and therapeutic target in several cancers. This study evaluates the clinical significance of AnxA2 in HCC progression. Methods: The Cancer Genome Atlas (TCGA) data was mined to assess AnxA2 mRNA expression in HCC and its correlation with tumor stage, grade, overall survival, and progression-free survival. Additionally, immunoblot analysis was conducted on tumor tissue samples to determine the AnxA2 expression in HCC patients. Results: Analysis of TCGA data revealed a significant upregulation of AnxA2 mRNA expression in HCC compared to normal liver tissues, correlating with higher pathological grades and stages and poor overall and progression-free survival. The immunoblot analysis further confirmed that the expression of AnxA2 was high in tumor tissues of HCC patients compared to matched adjacent non-tumorigenic liver tissues. Conclusion: These findings underscore the potential of AnxA2 as a biomarker for cancer aggressiveness and prognosis, highlighting its role as a promising therapeutic target. | en_US |
dc.identifier.uri | https://hdl.handle.net/20.500.12503/32591 | |
dc.language.iso | en | |
dc.title | Understanding the role of Annexin A2 expression in the incidence of Hepatocellular Carcinoma. | en_US |
dc.type | poster | en_US |
dc.type.material | text | en_US |